Haselsberger K, Maier T, Dominikus K, Holl E, Kurschel S, Ofner-Kopeinig P, Unger F
Department of Neurosurgery, Medical University, Graz, Austria.
J Neurol Neurosurg Psychiatry. 2009 Oct;80(10):1172-5. doi: 10.1136/jnnp.2008.156745.
This study investigated the efficacy of staged radiosurgical treatment for intracranial meningiomas exceeding 3 cm in diameter.
Between April 1992 and May 2008, staged gamma knife radiosurgery was performed in 20 patients with large benign meningiomas. 14 patients had undergone surgery at least once. The patients' ages ranged between 26 and 73 years (median 60.5). Tumour volumes measured between 13.6 and 79.8 cm(3) (median 33.3) and treatment volumes between 5.4 and 42.9 cm(3) (median 19.0). Of 41 treatments, the prescription dose at the tumour margin was 12 Gy for 33 treatments, 10 Gy for one treatment, 14 Gy for four treatments, 15 Gy for one treatment and 25 Gy for a further two treatments (median 12 Gy to a marginal isodose of 45%). Median follow-up was 7.5 years.
Tumour control was achieved in 90% of our series (25% tumour regression, 65% stable size). Two patients (10%) experienced tumour progression outlying the planning target volumes treated by an additional radiosurgical procedure. Thereafter tumour volume decreased in one patient and remained stable in the second one. Clinically, nine patients (45%) improved within the time of follow-up and 11 (55%) remained unchanged.
As a result of excellent tumour control at a low concomitant morbidity, staged radiosurgical treatment for meningiomas represents a safe treatment modality that can be recommended for meningiomas in critical locations either after incomplete surgery or as primary treatment for patients with significant comorbidity.
本研究调查了分期放射外科治疗直径超过3 cm的颅内脑膜瘤的疗效。
1992年4月至2008年5月,对20例大型良性脑膜瘤患者进行了分期伽玛刀放射外科治疗。14例患者至少接受过一次手术。患者年龄在26至73岁之间(中位年龄60.5岁)。肿瘤体积在13.6至79.8 cm³之间(中位体积33.3 cm³),治疗体积在5.4至42.9 cm³之间(中位体积19.0 cm³)。在41次治疗中,33次治疗的肿瘤边缘处方剂量为12 Gy,1次治疗为10 Gy,4次治疗为14 Gy,1次治疗为15 Gy,另外2次治疗为25 Gy(中位剂量为12 Gy至45%的边缘等剂量线)。中位随访时间为7.5年。
我们的系列研究中90%实现了肿瘤控制(25%肿瘤缩小,65%大小稳定)。2例患者(10%)出现肿瘤进展,超出了经额外放射外科治疗的计划靶体积。此后,1例患者的肿瘤体积减小,另1例保持稳定。临床上,9例患者(45%)在随访期间病情改善,11例(55%)保持不变。
由于在低并发症发生率的情况下实现了出色的肿瘤控制,脑膜瘤的分期放射外科治疗是一种安全的治疗方式,对于不完全手术后关键部位的脑膜瘤或合并严重疾病患者的初始治疗,均可推荐使用。